Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RXRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRecursion founder Chris Gibson to step down from Board in June 2026
Filed April 30, 2026 · Period ending April 28, 2026 · ~1 min read
Key Changes
-
medium
Founder and Board Chair Chris Gibson will not seek re-election when his term expires at the June 2026 annual meeting, transitioning to a strategic advisor role.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
low
Gibson's departure is not due to any disagreement with the company on operations, policies, or practices; he will remain Chair through the annual meeting.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
low
CEO Najat Khan confirmed Gibson will continue as an advisor, maintaining continuity with the founder's strategic input during the governance transition.
Exhibit 99.1 view on EDGAR →
Summary
Recursion Pharmaceuticals disclosed that founder and Board Chair Chris Gibson will step down from the Board when his term expires at the June 2026 annual meeting. The filing explicitly states his decision is not due to any disagreement with the company, and he will transition to a strategic advisor role.
This represents a planned governance evolution as the company continues under CEO Najat Khan, who recently joined in a leadership transition. For retail holders, this is a routine governance matter with no immediate concerns. Gibson's continued involvement as an advisor preserves institutional knowledge while allowing the Board to evolve.
The explicit "no disagreement" language and advisor arrangement suggest an orderly succession rather than a disruptive departure. The company is executing a planned transition that maintains founder input while adapting its governance structure.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Chris Gibson, Ph.D., will complete his current term through June 2026 and does not intend to seek re-election to the Company’s Board of Directors.
Recursion's founder and Board Chair, Chris Gibson, will step down from the Board when his term expires in June 2026. He will transition to a strategic advisor role. The company frames this as a planned transition supporting continuity under CEO Najat Khan, who joined in a recent leadership change.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 28, 2026, Christopher Gibson, Ph.D., Chair of the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Dr. Gibson’s decision to not stand for re-election did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Dr. Gibson will continue in his role as Chair of the Board and on the committees to which he was appointed until the expiration of his current term at the 2026 Annual Meeting.
The Board Chair, Christopher Gibson, will not seek re-election at the 2026 annual meeting, ending his tenure as a Class II director. The filing explicitly states his departure is not due to any disagreement with the company. He remains Chair and serves on three board committees until the annual meeting.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 22, 2026 · How we verify